Analisi strategica e modelli di business innovativi del settore farmaceutico

The reason why I decided to present this particular theme in my master's thesis is due obviously to the peculiarity of this sector but most of all, I would like to present an incredibly wide sector, unknown by usual Management's students, which includes and involves, all the world: directly, in terms of insiders and indirectly, in terms of customers. On the other hand, I wanted to analyze and present the main development practices of this industry and how they could be innovated being more effective and efficient. Pharmaceutical mergers and acquisitions have unique problems inherent in the operation of an increasingly complex industry. The existence of alliances and partnerships, sometimes very engaging in a concentrated market, challenges the classical and theoretical analysis of mergers and acquisitions. Added to this there are difficulties concerning valuations methods, induced by the degree of technicality and uncertainty related to research and development and both on post-integration method. In this work I will analyze the key trends in terms of renovation of the pharmaceutical business model to create value and consequently, I will further analyze the increasingly popular theme of open innovation applied to the pharmaceutical industry, as new source of value both in terms of less expansive acquisition and more profitable partnership for the future of drugs development. Therefore, the objective of this paper is to define the importance of business partnerships in the pharmaceutical sector, trying to explain, the reasons why they can represent a successful strategy for Big Pharma and which could be the key challenges for the future of these models.